🇪🇺 L19TNF in European Union

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

L19TNF (L19TNF) regulatory status in European Union.

Marketing authorisation

EMA

Application: EMEA/H/C/005651
Marketing authorisation holder: Philogen S.p.A.
Local brand name: Nidlegy
Indication: Neoadjuvant treatment of adult patients with locally advanced fully resectable melanoma 
Status: withdrawn

Read official source →

Frequently asked questions

Is L19TNF approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for L19TNF in European Union?

Philogen S.p.A. holds the EU marketing authorisation.